An observational study in Children Brain Injury, sponsored by University Hospital, Grenoble. Recruiting at 2 sites in France. Open to participants aged 1 Month to 17 Years. Per ClinicalTrials.gov, last updated 2025-04-02.
Sponsored by University Hospital, Grenoble · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Craniocerebral Trauma with a site in France — 6 open to participants now, 6 under way, none of them phase 3. Craniocerebral Trauma · France.
Among the 36 studies in Craniocerebral Trauma with a site in France, this one is the 14th largest by planned enrollment of the 21 observational ones that give a count, is one of 2 that started in 2024, is one of 21 observational ones, and was the 31st registered.
253 studies on the registry are indexed under Craniocerebral Trauma; 45 are open to participants now.
Browse Craniocerebral Trauma studies →6 of the 36 studies in Craniocerebral Trauma with a site in France are open now. Recruiting first, the newest first:
University Hospital, Toulouse · Sites in France
Ages 18–60
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 18–75
University Hospital, Strasbourg, France · Sites in France
Ages 18+
CHU de Reims · Sites in France
Ages 18+
Hospices Civils de Lyon · Sites in France
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 25 Craniocerebral Trauma studies recruiting now, 8 (32%) set no upper age limit and 14 (56%) stop at 75 or younger; 8 take children under 18; 1 takes healthy volunteers.
This study: 1 Month to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 5
First in 1983; this study’s year is marked. 2 started in 2024.
This study's planned enrollment of 90 is below the median of 180 across 111 observational studies indexed under Craniocerebral Trauma.
Median enrollment 60 across the 15 interventional studies, 130 across the 21 observational. Of the 22 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 36 have an industry lead sponsor. The 10 most frequent:
University Hospital, Grenoble is the lead sponsor of 838 studies on the registry; 208 are open to participants now.
University Hospital, Grenoble has 1 study filed under Craniocerebral Trauma — fewer than ten, so there is no comparison to draw.
2 of the studies in Craniocerebral Trauma with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06077695University Hospital, ToulouseCognitive Remediation of Working Memory Post Head Trauma | 2027-07-06 |
| NCT06642896University Hospital, GrenobleQuantitative Pupillometry in Brain Injury Children : Variation After Osmotherapy | 2027-10-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 36 studies in Craniocerebral Trauma with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Intracranial hypertension (ICH) is a common and serious complication in children admitted to pediatric intensive care units. It is primarily caused by traumatic brain injury but can also result from brain malformations, brain tumors, or neuro-meningeal infections. Rapid identification of ICH in acute settings is crucial to ensure prompt management and mitigate potential consequences, such as severe neurological sequelae or death.
The assessment of the pupillary light reflex is one of the key clinical parameters used to identify ICH in children with neurological injuries. This clinical sign is correlated with neurological prognosis. During an episode of ICH, regardless of the underlying cause, the oculomotor nerve becomes compressed between the midbrain and the temporal lobe, leading to anisocoria (unequal pupil sizes) and loss of pupillary reactivity. Other factors, such as episodes of ischemia or hypoperfusion in the midbrain, can also contribute to decreased pupillary reactivity.
Traditionally, the pupillary light reflex is assessed using a simple light source, with subjective evaluation by a healthcare professional. However, this method has significant inter- and intra-individual variability. Quantitative pupillometry offers a more objective and reproducible way to evaluate pupillary reactivity. In adults, some parameters are well-known indicators of ICH, such as a constriction velocity of less than 0.6 mm/sec and a constriction percentage below 10%. The constriction percentage can be simplified with the Neurological Pupil index (NPI), which ranges from 0 to 5. An NPI of 4 or 5 is considered to indicate good pupillary reactivity. The two quantitative pupillometers currently on the market (Neurolight, Neuroptics) appear to provide similar data for most variables assessed. However, there are few studies evaluating this tool in pediatric patients with neurological injuries.
One study on quantitative pupillometry found that children with neurological injuries and an intracranial pressure (ICP) above 20 mmHg had significantly lower pupillary reactivity, NPI, constriction percentage, and dilation and constriction velocities compared to children without ICH.
Osmotherapy is a commonly used pharmacological intervention in pediatrics to lower intracranial pressure and improve cerebral perfusion pressure. Based on the work of Freeman et al., we hypothesize that the pupillary constriction percentage improves after osmotherapy in children with neurological injuries.
children aged 1 month to 17 years with brain lesion receiving osmotherapy
Inclusion Criteria:
Exclusion Criteria:
Admission to the pediatric intensive care or neurosurgical intensive care unit, pupillometry measurement before and after osmotherapy treatment
Device: pupillometer
feasibility of pupillometry in children for different age groups and obtain baseline values for non-neurologically sedated children in 4 age groups from 0 to 17 years of age in intensive care and the operating room
Device: pupillometer
describe the feasibility of pupillometry measurements in sedated but non-cerebrosed children in intensive care and the operating room
Pupillometry measurements at 5 and 25 minutes for children treated with osmotherapy, followed by measurements twice a day during hospitalization in the intensive care unit
to describe and evaluate the variation in the percentage of pupillary constriction (CON) before, and after osmotherapy in neuro-injured children.
Delta (in percentage difference, and in delta of values) of the constriction (CON) between the last available measurement before the osmotherapy was started, and the measurement 5 minutes after the end (at 25 minutes after the start of the osmotherapy). For each child, the eye with the lowest constriction (CON) value before osmotherapy will be considered.
Time frame: at 10 days
Describe the feasibility of pupillometry in children for different age groups, and obtain baseline values for the sedated, non-neurosed child.
Success rate in obtaining pupillometric values for different age groups. Pupillometric values: QPI (quantitative pupillometry index) in intensive care and the operating room
Time frame: at 1 minute and 25 minutes
Describe the feasibility of pupillometry in children for different age groups, and obtain baseline values for the sedated, non-neurosed child.
Success rate in obtaining pupillometric values for different age groups. Pupillometric values: latency (LAT) in intensive care and the operating room
Time frame: at 1 minute and 25 minutes
Describe the feasibility of pupillometry in children for different age groups, and obtain baseline values for the sedated, non-neurosed child.
Success rate in obtaining pupillometric values for different age groups. Pupillometric values: constriction velocity (ACV) and dilatation velocity (ADV) in mm/sec in intensive care and the operating room
Time frame: at 1 minute and 25 minutes
Describe the feasibility of pupillometry in children for different age groups, and obtain baseline values for the sedated, non-neurosed child.
Success rate in obtaining pupillometric values for different age groups. Pupillometric values: minimum (MIN) and maximum (MAX) pupillary diameter in mm in intensive care and the operating room
Time frame: at 1 minute and 25 minutes
In the age subgroup of children with an intracranial pressure (ICP) sensor (pathological if ICP more than 20mmHg), evaluate the relationship between intracranial pressure and the various pupillometry values (LAT).
Assessing the association between latency in sec (LAT) and ICP (mmhg)
Time frame: per 12h during 10 days
In the age subgroup of children with an intracranial pressure (ICP) sensor (pathological if ICP more than 20mmHg), evaluate the relationship between intracranial pressure and the various pupillometry values (QPI).
Assessing the association between measurements of pupillometry, QPI, quantitative pupillometry index
Time frame: per 12h during 10 days
In the age subgroup of children with an intracranial pressure (ICP) sensor (pathological if ICP more than 20mmHg), evaluate the relationship between intracranial pressure and the various pupillometry values.(CON)
Assessing the association between measurements of pupillometry, percentage of constriction (CON) and ICP.
Time frame: per 12h during 10 days
In the age subgroup of children with an intracranial pressure (ICP) sensor (pathological if more than 20mmHg), evaluate the relationship between intracranial pressure and the various pupillometry values (Max; Min)
To asses association between intracranial pressure and minimum et maximum pupillary diameter (in mm).
Time frame: per 12h during 10 days
In the age subgroup of children with an intracranial pressure (ICP) sensor (pathological if more than 20mmHg), evaluate the relationship between intracranial pressure and the various pupillometry values. (ACV and ADV)
To asses association between ICP and pupillometry values : constriction velocity (ACV) and dilatation velocity (ADV) in mm.sec
Time frame: per 12h during 10 days
Comparison of pupillometry values between neuro-sedated and non-neuro-sedated children, adjusting for age
measurement of pupillometric parameters : latence (in sec)
Time frame: at 1 and 25 minutes
Comparison of pupillometry values between neuro-sedated and non-neuro-sedated children, adjusting for age.
measurement of pupillometric parameters : quantitative pupillometry index, pupil constriction
Time frame: at 1 and 25 minutes
Comparison of pupillometry values between neuro-sedated and non-neuro-sedated children, adjusting for age.
measurement of pupillometric parameters : Minimum and maximum pupillary diameter (in mm)
Time frame: at 1 and 25 minutes
Comparison of pupillometry values between neuro-sedated and non-neuro-sedated children, adjusting for age.
measurement of pupillometric parameters constriction velocity (ACV), dilatation velocity (ADV) in mm/sec
Time frame: at 1 and 25 min
Describe the evolution of different pupillometry measurements before and after osmotherapy
Measure of pupillometry: CON and QPI after osmotherapy administration
Time frame: at 15 , 25, 35, 45, 60, 120, 240 minutes
Describe the evolution of different pupillometry measurements before and after osmotherapy
Measure of pupillometry : constriction velocity (ACV), dilatation velocity (ADV) in mm/sec
Time frame: [Time Frame: at 15 , 25, 35, 45, 60, 120, 240 minutes]
Describe the evolution of different pupillometry measurements before and after osmotherapy
Measure of pupillometry: latence (in mm)
Time frame: [Time Frame: at 15 , 25, 35, 45, 60, 120, 240 minutes]
Describe the evolution of different pupillometry measurements before and after osmotherapy
Measure of pupillometry: Min and max pupillary diameter in mm.
Time frame: at 15 , 25, 35, 45, 60, 120, 240 minutes
Assessing the relationship between transcranial Doppler (CTD) results: pulsatility index (PI) and diastolic velocity (Vd)
Repeated pupillometry measurements : (LAT) latence in sec and transcranial doppler
Time frame: 2 times a day for 10 days or on discharge from hospital
Assessing the relationship between transcranial Doppler (CTD) results: pulsatility index (PI) and diastolic velocity (Vd)
Repeated pupillometry measurements QPI and CON and transcranial doppler
Time frame: 2 times a day for 10 days or on discharge from hospital
Assessing the relationship between transcranial Doppler (CTD) results: pulsatility index (PI) and diastolic velocity (Vd)
Repeated pupillometry measurements (Maximum and minimum pupillary diameter in mm) and transcranial doppler
Time frame: 2 times a day for 10 days or on discharge from hospital
Assessing the relationship between transcranial Doppler (CTD) results: pulsatility index (PI) and diastolic velocity (Vd)
Repeated pupillometry measurements (constriction velocity (ACV) and dilatation velocity (ADV) in mm.sec) and transcranial doppler
Time frame: 2 times a day for 10 days or on discharge from hospital
Plan to share: No — This is an observational study, which does not modify the management of children with brain lesions, nor does it generate additional therapies.
Started Nov 2024 (actual). Primary completion is estimated for Oct 2027, 35 months after the start.
Of 43 non-industry observational studies under Craniocerebral Trauma, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's planned 35 months is close to that.
Counting every sponsor, half of 43 studies reached it within 32 months; a quarter within 15 and three quarters within 49.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Grenoble →